Chinese Pharmacopeia Commission, Waters Inaugurate Joint Lab in China

From DCAT Value Chain Insights (VCI)

By Regulatory News posted 01-30-2015 14:00


The Chinese Pharmacopeia Commission (ChP) and Waters Corporation, a provider of analytical instrumentation and related products and services, have inaugurated their Joint Open Laboratory in Beijing. The analytical laboratory will be jointly operated by ChP and Waters.

Focus areas include research of pharmacopoeia standards, development of testing methods, methods validations, and basic and advanced technical training of pharmacopoeia detection methods. The laboratory is also anticipated to play a role as one of the national technical support centers in the field of Chinese pharmaceutical standards.

The joint open lab spans 400 square meters and is located within the laboratory building of the Beijing Zhendong Guangming Drug Research Institute. Outfitted with Waters' chromatography and mass spectrometry technologies, the facility is set to support pharmacopeia standards in China. The opening ceremony, hosted by ChP, included officials from China's pharmacopeia supervisory bodies, industry professionals and technicians, and representatives from Chinese pharmaceutical enterprises reviewing future construction and operation prospects for the lab.

The ChP is an official and authoritative compendium of drugs and has been in place since 1950, publishing compendiums in 1953, 1963, 1977, 1985, 1990, 1995, 2000, 2005, and 2010. Formerly reporting under the Chinese Ministry of Health, it is now is an affiliated commission of the newly formed Chinese Food and Drug Administration (CFDA). ChP is also officially recognized by the World Health Organization.

Source: Waters Corporation


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription